

## HIV subtypes in Scotland, 2000–2006

D. L. YIRRELL<sup>1</sup>\*, L. SHAW<sup>2</sup>, E. CAMPBELL<sup>4</sup>, S. M. BURNS<sup>3</sup>, S. O. CAMERON<sup>4</sup>  
AND D. GOLDBERG<sup>2</sup>

<sup>1</sup> *Department of Medical Microbiology, Ninewells Hospital, Dundee, Scotland, UK*

<sup>2</sup> *Health Protection Scotland, Glasgow, Scotland, UK*

<sup>3</sup> *Specialist Virology Centre, Royal Infirmary of Edinburgh, Scotland, UK*

<sup>4</sup> *Specialist Virology Centre, Gartnavel General Hospital, Glasgow, Scotland, UK*

(Accepted 23 August 2007; first published online 9 October 2007)

### SUMMARY

The purpose of this study was to document the dynamics of HIV-1 subtypes in Scotland over a 6-year period. Viral RNA from all-new diagnoses was amplified by nested PCR and sequenced in the gag and/or env regions. Subtype was assigned by phylogenetic analysis, and aligned with demographic data including likely route and geographical origin of infection. We present data on 80% of all new diagnoses in Scotland between April 2000 and April 2006. Within the background of an expanding epidemic, subtype B predominates in men who have sex with men and intravenous drug users but there is a small but consistent number of UK-acquired infections in these risk groups caused by non-B subtypes. In heterosexuals, non-B subtypes acquired abroad, especially Africa, are still the largest group but again UK-acquired numbers are rising. The social and clinical significance of the spread of non-B subtypes in different ethnic and risk groups remains to be established.

### INTRODUCTION

The global HIV/AIDS epidemic is dominated by members of the HIV-1 group M (Main), groups N, O and HIV-2 representing only a minority of infections. The M group is further subdivided into nine subtypes denoted by the letters A–D, F–H, J and K, subtypes E and I have been reclassified. Subtypes A and F are further subdivided into sub-subtypes A1, A2 and F1, F2, and due to their relative similarity it has proposed that subtypes D and B could represent subdivisions of the same subtype [1]. Subtypes have traditionally had

a broadly geographical and risk group distribution, suggestive of a limited number of local introductions [2]. In addition to subtypes, an increasing number of inter-subtype recombinant viruses have been described. Some are unique to individuals, but others have been shown to maintain their characteristic mosaic structure following transmission, and have been termed circulating recombinant forms (CRF). So far at least 21 have been described [3, 4].

The importance of subtype is both clinical and epidemiological. Epidemiologically, the epidemic of HIV in the Scotland (and the United Kingdom) was established in men who have sex with men (MSM) and intravenous drug users (IDU) and was almost exclusively caused by subtype B [5]. In contrast, in the majority of the world the primary route of transmission has been, and continues to be, heterosexual

\* Author for correspondence and reprints: Dr D. L. Yirrell, Consultant Clinical Scientist, Department of Medical Microbiology, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK.  
(Email: dave.yirrell@nhs.net)

contact, and non-B subtypes predominate [6]. Since 2000 the most common route of infection in newly diagnosed cases in Scotland has been heterosexual contact [7].

Knowledge of the subtype of infecting virus combined with route and geographical origin of infection can therefore inform health-care services of changes in behaviour and assist in the targeting of measures to reduce transmission. Clinically, knowledge of the subtype may affect patient management at a number of levels. Observational evidence suggests that non-B subtypes are more able to transmit by the heterosexual route [8]; that the rates of clinical decline especially relative to viral load may vary with subtype [9]; that different subtypes may respond differently to drug therapy [10] and that some subtypes may be inherently more able to develop resistance to therapy [11]. Since much of this is currently unproven, it is prudent to monitor the situation such that evidence can be accrued.

In April 2000, a surveillance system for HIV subtype was established [12] the purpose of which was to document the changing patterns of HIV subtype in all new diagnoses in Scotland. Here we present the data generated over the 6-year period, April 2000–April 2006.

## METHODS

### Design

The design is a subtype analysis of HIV infection among newly diagnosed individuals in Scotland over a 6-year period and the alignment of the resulting data with corresponding demographic and risk information.

### Patients and samples

Virus from all new HIV diagnoses, confirmed by Scotland's two specialists testing laboratories, was eligible for subtype analysis using residual sera or plasma specimens submitted for HIV diagnosis and viral load testing, respectively.

### Laboratory methods

RNA was extracted from patient sera or plasma and amplified in the p17/p24 region of the *gag* gene by nested RT-PCR and sequenced. Sequences were aligned with a homologous region from reference

strains obtained from the Los Alamos Database and subtype assigned by association on phylogenetic trees [12]. If the subtype was unequivocally B or C it was reported as such. If not, further sequencing was attempted in the v3/v4 region of the *env* gene to provide supporting evidence [12]. The subtype was then reported using all available data. Additional sequencing was particularly necessary for subtype A viruses since this subtype contributes to several different CRF which are difficult to distinguish using the *gag* region alone.

### Patient demographic and risk information

Since 1985 HIV testing laboratories throughout Scotland have reported cases of HIV seropositivity to Health Protection Scotland (HPS). Reporting is estimated to be 99% complete and the information held on each case includes gender, date of birth, soundex code of surname, first part of postal code of residence, date of earliest positive specimen and risk exposure; data are collected through the use of a national HIV test form. For cases whose risk status, as recorded on request forms by the attending clinician, is injecting drug use and/or homosexual/bisexual male, no active surveillance to verify this information is undertaken. For cases whose risk status is recorded as either child of infected mother or blood/blood product recipient, verification is conducted through liaison with the UK's Institute of Child Health (which coordinates UK-wide, clinician-based, HIV paediatric and obstetric surveillance systems) and the Scottish National Blood Transfusion Service, respectively. Where heterosexual exposure is the only risk indicated or where incomplete information is provided, contact is made with the patient's physician. For the former group, the enquiry seeks to elucidate the risk status of the case's sexual partner(s) (e.g. IDU), in which part of the world the likely exposure occurred and, if this was outside the United Kingdom, whether or not the case was an indigenous Scot who travelled abroad on vacation/business.

## RESULTS

### General trends

The number of HIV diagnoses has risen steadily over the period of this study from 134 in 2000/2001 to its current peak of 400 in 2005/2006 (Table 1). This increase has been in both subtype B and non-B

Table 1. Incidence of B and non-B HIV infections in Scotland by risk group, origin and year of diagnosis

Risk group	Acquired	2000			2001			2002			2003			2004			2005			Total
		B	Non-B	ND	B	Non-B	ND	B	Non-B	ND	B	Non-B	ND	B	Non-B	ND	B	Non-B	ND	
Blood/tissue	Non-UK	1	1	1	2	2	—	—	—	—	—	—	—	—	—	—	—	—	—	10
	UK	—	—	—	—	1	—	—	—	—	—	—	—	—	—	—	—	—	—	2
Heterosexual	Non-UK	5	32	2	5	68	12	8	19	11	112	29	4	73	60	558	4	73	60	558
	UK	14	4	1	11	5	9	17	2	21	17	3	11	21	17	211	3	11	21	211
IDU	Non-UK	2	—	—	5	1	1	1	—	1	—	—	—	—	—	—	—	—	—	16
	UK	8	—	2	9	1	2	8	—	5	—	3	5	4	8	71	2	6	4	8
MSM	Non-UK	4	1	—	5	9	3	9	2	8	9	2	5	12	6	11	12	6	11	90
	UK	45	2	6	46	3	8	56	5	67	4	89	11	4	85	493	1	4	33	493
Other	Non-UK	—	1	—	—	6	—	—	—	1	—	—	—	—	—	—	—	—	—	28
	UK	1	—	1	1	2	1	4	1	4	1	4	2	2	1	2	1	2	3	28
Total		80	41	13	82	52	31	107	99	113	101	40	144	157	120	153	127	120	153	1553

IDU, Intravenous drug users; MSM, men who have sex with men. ND; No data (either failed to amplify or no sample was available); MSM, includes 12 cases where risk is MSM & IDU, all subtype B. Other (2 haemophiliac, 24 MTC/perinatal, 76 risk not yet established).





Fig. 1. Origin of infection of (a) subtype B, (b) subtype non-B and (c) untyped HIV infections in Scotland by year of diagnosis. ■, Non-UK; □, UK.

infections, but the rise is much greater in the latter group, such that, of those that have been assigned a subtype, the percentage of non-B infections has increased from 34% (41/121) in 2000/2001 to approximately parity (120/247, 49%) in 2005/2006. Indeed at its height, in 2004/2005 non-B subtypes predominated (157/301, 52%).

**UK vs. non-UK acquired infections**

Subtype B infections were mainly acquired within the United Kingdom, the number of non-UK-acquired subtype B infections remaining fairly constant over the study period (Fig. 1a), with an annual median






**Fig. 2.** Trends in UK-acquired non-subtype B HIV infections diagnosed in Scotland, by (a) subtype and (b) risk group. (a) —, Subtype C; ---, subtype A (includes CRF A/E and A/G); ·····, other subtypes. (b) —, Heterosexual; —, men who have sex with men (MSM); ---, intravenous drug users (IDU); ·····, other.

non-UK- acquired subtype B infections originated in the Americas/Europe. In subsequent years increasing numbers of heterosexuals acquired their HIV from Africa/Asia, a trend which manifests itself in MSM from 2003/2004.

In contrast, most non-B infections acquired outside the United Kingdom originated in Africa (Fig. 4). This was true for all non-B subtypes with the exception of CRF01\_AE, which dominates South-East Asia, a fact reflected by its origin in diagnoses made in Scotland.

**DISCUSSION**


The observation that subtype B viruses are rare in the heterosexually driven epidemic in Africa, the region from which all subtypes are thought to have originated, has led to the opinion that subtype B is not well suited to this mode of transmission. Indeed, perhaps it has been out-competed in this environment by its closest relative, subtype D, which circulates in East Africa in direct competition with subtype A [13]. There are also concerns about non-B subtypes causing more aggressive disease, responding differently to anti-retroviral therapy or having lower genetic



**Fig. 3.** Origin on non-UK-acquired subtype B infections by year or diagnosis in (a) heterosexuals, (b) intravenous drug users (IDU) and (c) men who have sex with men (MSM). ■, Africa/Asia; □, Europe/Americas.

barriers to the development of drug resistance in some subtypes [14, 15]. Overall there is a fear of the unknown brought about by non-B subtypes entering a different host range via different transmission routes when experience at both an individual and population level is limited. The sensible approach therefore seems to monitor the situation until sufficient evidence accrues to make evidence-based decisions.

In this paper we have presented HIV subtype, origin of infection and risk-group data on 85% (976/1153) of all new diagnoses of HIV over a 5-year period for the whole of Scotland. The final year remains less complete although where data is available, previous trends appear to continue. Where subtype is missing, three quarters of this was due to an inability to amplify by PCR. Where data was available for such specimens, they invariably proved to have either



**Fig. 4.** Subtype and origin of non-B HIV subtypes acquired outside the United Kingdom. ■, Europe/Americas; ■, Africa; □, Asia.

low or undetectable viral loads. We are therefore confident that failure due to sequence variation was not a significant contributor to missing data.

In 2000 the ratio of B to non-B infections was about 2:1. Two years later this had decreased to approximately parity and has remained steady at this level. However this is against a background of a documented recent rise in the incidence of infection in MSM, a risk group dominated by subtype B viruses [7].

In 2000 63% (84/134) of new HIV infections were acquired in the United Kingdom but this declined steadily over the following 3 years to 51% by 2003/2004. The majority of infections acquired abroad have been assigned to the heterosexual route of infection, reflecting the position of this transmission route worldwide. Indeed the majority of heterosexually acquired infections originate outside the United Kingdom. Between 2000 and 2002 heterosexual transmission constituted 44% of all new infections, but between 2002 and 2005 this figure had risen to >50% (53%, 52% and 55% respectively).

The most common non-B subtype identified was subtype C. This reflects its position as the most common subtype worldwide, dominating southern Africa and the Indian subcontinent [15]. The next most numerous subtype was A and CRF containing sections of this subtype, i.e. CRF01\_A/E, and CRF02\_A/G. For both convenience and technical reasons, within this paper, these subtypes are often taken together. HIV subtyping is not an exact science and it is getting increasingly difficult to assign a virus with absolute confidence. The majority of subtype assignment is based on a few hundred bases of a single or perhaps two genes. Although we have employed what is regarded as the gold standard of subtyping, namely phylogenetic comparison, the sum of the sequence may hide sections of another subtype within its length

[16]. In other cases a *gag* gene could be confidently assigned to subtype A, but sequence from the *env* gene was equally confidently assigned to subtype G. Thus, the virus was assigned A/G, irrespective of whether or not its mosaic pattern resembled CRF02\_AG. If however, we were unable to generate sequence data from the *env* gene, it remained designated subtype A. Thus combining numbers of A's with A/\*, is technically sensible, but from an epidemiological view it is confusing since pure subtype A is associated with East Africa, A/G with West Africa and A/E with South-East Asia [15].

We are fortunate in Scotland in knowing, in most cases, the likely country of origin of infection and this matched the sequence data in most cases. However, the converse, predicting the country of origin from limited sequence data can be misleading. In Scotland most of the non-UK-, non-B-acquired infections originated from Sub-Saharan Africa, irrespective of subtype. Subtype CRF01\_AE was the only significant deviation from this rule, originating predominantly from Asia.

CRF are named not only because they are composed of different subtypes but also they have spread between a number of individuals and maintained their distinctive mosaic structure. With the generation of more sequence data it is becoming increasingly clear that there are other recombinant forms of HIV which may transmit as a stable form or which are unique to that individual [16]. Thus, for example, the A/G, non-CRF02\_A/G described above, may have been generated within that individual or may have been acquired as a recombinant. The mixing of more individuals from different countries, harbouring a variety of HIV subtypes, provides the opportunity for the generation of more novel recombinant viruses. Thus, whilst viruses infecting individuals in the majority of the world will reflect the local homogenous risk group strain, a minority in cosmopolitan cities have the potential for developing unique viruses of unknown pathogenesis. Unfortunately it is the latter with which we in the United Kingdom are likely to have to come to terms with.

In this study we identified a wide range of HIV subtypes other than A, B, C and known CRF, indicating that our methodology is robust in being able to detect sequence diversity. Although each exotic subtype only constituted a few sporadic isolates on a population level, individually they may provide valuable information with regards pathogenesis in the individual and spread within a community.

We have documented the HIV subtype and origin of infection of about 80% of all new diagnoses in the whole of Scotland over a 6-year period. There is considerable viral diversity, subtype B representing only half of all isolates. Whilst this subtype still predominates in MSM and IDU there is a small but significant number of UK-acquired infections in these risk groups caused by non-B subtypes. In heterosexuals, non-B subtypes acquired abroad are still the largest group, but again UK-acquired numbers are rising. Subtyping is not always a straightforward or simple process and we would predict that the situation is likely to become more rather than less complicated in multicultural Britain. Therefore, to enable an assessment of the impact of subtype diversity on a clinical and epidemiological level continued monitoring is essential.

#### ACKNOWLEDGEMENTS

This work was funded by the National Services Division of the Scottish Executive.

#### DECLARATION OF INTEREST

None.

#### REFERENCES

1. **Kuiken C, et al. (eds).** *HIV Sequence Compendium 2002*. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, LA-UR no. 03-3564, 2002.
2. **Walker PR, et al.** Comparative population dynamics of HIV-1 subtypes B and C: subtype-specific differences in patterns of epidemic growth. *Infection, Genetics and Evolution* 2005; **5**: 199–208.
3. **Leitner T, et al.** HIV-1 subtype and circulating recombinant form (CRF) reference sequences. In: Leitner T, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, Korber B, eds. *HIV Sequence Compendium 2005*. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, LA-UR no. 06-0680, 2005, pp. 41–48.
4. **Geretti AM.** HIV-1 subtypes: epidemiology and significance for HIV management. *Current Opinion in Infectious Diseases* 2006; **19**: 1–7.
5. **Hue S, et al.** Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. *Proceedings of the National Academy of Sciences USA* 2005; **102**: 4425–4429.
6. **UNAIDS.** Joint United Nations Programme on HIV/AIDS (<http://www.unaids.org>). Accessed December 2006.
7. **Health Protection Agency.** New diagnosis slide set ([http://www.hpa.org.uk/infections/topics\\_az/hiv\\_and\\_sti/hiv/epidemiology/introduction.htm](http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/hiv/epidemiology/introduction.htm)). Accessed December 2006.
8. **Mastro TD, et al.** Why do subtypes segregate among persons with different risk behaviours in South Africa and Thailand? *AIDS* 1997; **11**: 113–116.
9. **Senkaali D, et al.** The relationship between HIV-1 disease progression and v3 serotype in a rural Ugandan cohort. *AIDS Research and Human Retroviruses* 2004; **20**: 932–937.
10. **Spira S, et al.** Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. *Journal of Antimicrobial Chemotherapy* 2003; **51**: 229–240.
11. **Brenner B, et al.** A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross resistance to non-nucleoside reverse transcriptase inhibitors. *AIDS* 2003; **17**: F1–5.
12. **Yirell DL, et al.** HIV-1 Subtype in Scotland: the establishment of a national surveillance system. *Epidemiology and Infection* 2004; **132**: 693–698.
13. **Yirell DL, et al.** HIV-1 subtype dynamics over a 10 year period in a rural Ugandan cohort. *International Journal of STD AIDS* 2004; **15**: 103–106.
14. **Peeters M, Toure-Kane C, Nkengasong JN.** Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. *AIDS* 2003; **17**: 2547–2560.
15. **Wainberg MA.** HIV-1 subtype distribution and the problem of drug resistance *AIDS* 2004; **18**: S63–S68.
16. **Yirell DL, et al.** Inter and intra-genic inter-subtype HIV-1 recombination in rural and semi-urban Uganda. *AIDS* 2003; **16**: 279–286.